In 2001, we reported a case of refractory primary B-cell prolymphocytic leukemia (B-PLL) treated with allogeneic stem-cell transplantation with reduced-intensity conditioning (RIC) fludarabine-based regimen. At that time, complete remission (CR) was confirmed at almost 1 year after transplantation. 1 Since that time, the clinical course has been marked by two immunological complications. In April 2001, warm-antibody hemolytic anemia was diagnosed and treated with steroids leading to a CR. In January 2002, the patient was hospitalized because of clinically symptomatic idiopathic thrombocytopenia, resistant to immunoglobulin and steroids. Consequently, the patient underwent splenectomy with full and durable recovery of platelets. Histological examination of spleen did not show pathological prolymphocytes, confirming a CR status. The occurrence of autoimmune cytopenia following several months from transplantation is of particular interest. We did not identify any precipitating factors, such as infection or drugs, before either episode. It has been hypothesized that, in a context of ABO and other alloantigen differences, the persistence of recipient immunoglobulin and hematopoietic cells could explain immune reactions. 2 However, in this case, the donor/recipient pair was matched for ABO and other alloantigen systems, excluding this hypothesis. Therefore, more complex phenomena were likely, including a break in peripheral tolerance.
After a follow-up of 5 years (March 2005), she remains in continuous CR without signs of chronic GvHD and has full donor chimerism. Since our report, almost 150 patients with chronic lymphocytic leukemia (CLL) have been transplanted using RIC regimens 3-7 with a progression-free survival ranging from 69 to 72%. In Faulker's 3 study, PLL patients were included but results were not reported separately from the CLL group. However, the overall survival in this group was around 70%, with a median follow-up of 1.4 years.
In conclusion, the favorable long-term outcome of our refractory B-PLL patient after allogeneic stem-cell transplantation conditioned with nonmyeloablative regimen strongly suggests the possibility of cure. 
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